Australia: One For All, And All For One? A Unified Approach To Therapeutic Goods Promotion

Last Updated: 9 October 2009
Article by Amanda Turnill

Key Points:
Government-led consideration is currently being given to whether a single code should apply to medical devices and technology, pharmaceuticals (including generics) and complementary medicines.

The relationship between members of the therapeutic goods industry and health care professionals (HCPs) is currently an area of considerable debate. It seems as though every week there is another newspaper, radio program, television network or journal publisher that has something to say about how this relationship is, or ought to be, managed.

That debate has gathered momentum in the context of proposed changes to the laws and codes that govern the promotion of therapeutic goods and dealings between industry and HCPs. The Federal Parliamentary Secretary for Health, Mark Butler, has entered the debate to initiate stakeholder consultation about whether changes are needed to achieve a "level playing field on marketing obligations within the therapeutic goods industry" and to address the issue of improper influence in marketing.

This article considers some of the triggers for the current focus and selected reform proposals. Government-led consideration is currently being given to whether a single code should apply to medical devices and technology, pharmaceuticals (including generics) and complementary medicines. While it is early days, many stakeholders have expressed concerns that a single code approach would be impractical.

Existing regulation

The existing system of regulation is a complex and fragmented combination of laws (primarily the Therapeutic Goods Act 1989 (Cth) and accompanying Regulations and Codes) and separate industry codes. Industry groups that have developed or are in the process of developing codes of conduct include Medicines Australia, the Medical Technology Association of Australia, the Generic Medicines Industry Association, the Complementary Healthcare Council and the Australian Self-Medication Industry.

Various medical colleges and associations such as the Australian Medical Association and the Royal Australasian College of Physicians also have codes of conduct incorporating provisions that address professional independence and conflicts of interests. In some Australian states, the legislation governing the registration of HCPs addresses these issues by including them in prescribed categories that deal with professional conduct.

Pharmaceutical companies are often at the centre of the debate about the relationship between HCPs and industry. Given the legal prohibition on direct to consumer advertising of prescription pharmaceuticals, marketing activity is chiefly directed at HCPs. For innovator pharmaceutical companies (but not generics), this field is governed by the Medicines Australia Code of Conduct (MA Code) which is the most rigorous of the industry codes.

Medicines Australia Code of Conduct Ed. 16

The MA Code complements the Therapeutic Goods Act and Regulations. The MA Code must be authorised by the Australian Competition and Consumer Commission (ACCC). Authorisation provides immunity from court action for conduct that may otherwise contravene laws which prohibit anti-competitive conduct.

The MA Code is updated approximately every three years. Following a consultation process, authorisation will be granted when the ACCC is satisfied that the public benefit of the Code outweighs any public detriment.

Applications for authorisation of Edition 16 of the MA Code were submitted to the ACCC on 30 June 2009 and 12 August 2009. This Edition is expected to commence operation on 1 January 2010. It will be the culmination of a lengthy and detailed consultation process, complete with an independent audit by Dr Simon Longstaff of the St James Ethics Centre.

Key proposed changes to the Code include:

1. Additional training requirements for company representatives and employees involved in preparing or approving promotional material to be familiar with Australian privacy and trade practices legislation.
2. Additional restrictions on advertising. Some examples include a complete prohibition on advertising prescription medicines in electronic prescribing software; new provisions dealing with the use of "social media" such as Facebook, YouTube, MySpace and Twitter for the promotion of prescription medicines; and a general prohibition on giving brand name reminders to HCPs unless they are educational and/or directly related to the practice of medicine or pharmacy.
3. Further measures which are said to be designed to lead to increased accountability and transparency of industry conduct. For example, specific regulation of relationships between pharmaceutical companies and health consumer organisations; further restrictions on the circumstances in which financial support and other benefits can be provided to HCPs by pharmaceutical companies; and new provisions extending the Code to cover interactions between a pharmaceutical company and healthcare professionals when conducting clinical research.
4. An increase in the maximum fines for moderate (from $100,000 to $150,000); severe (from $100,000 to $200,000; and $250,000 if activities have ceased and there is no opportunity for corrective action); and repeat breaches (from $200,000 to $250,000) of the Code. These increases are consistent with a trend to increase fines each time the Code is revised. A new fine of up to $50,000 for failure to pay a fine within 30 days has also been introduced.

The updated draft MA Code appears to have been well received by stakeholders. Notably, even those who in the past could be described as having been critical of the MA Code, and the industry generally, have publicly congratulated Medicines Australia on its extensive consultation process and proactive approach to strengthening the Code. Of course, some areas of disagreement remain.

What is most interesting is the push that the new MA Code has generated for changes to how other players in the therapeutic goods industry are regulated. There is now a lively debate about working towards consistent regulation across the innovator and generic pharmaceutical industries, and extending that regulation to devices, medical technology, over-the-counter and complementary therapeutic goods.

Triggers and recent events

Appropriate governance of the relationship between industry and HCPs is an ongoing issue. It is well recognised that companies that develop therapeutic advances and possess much of the relevant information about them have a role to play in educating HCPs so that medicines are used safely and effectively. Industry is responsible for and funds a significant percentage of HCP continuing education and makes an important philanthropic contribution to healthcare endeavours. However, some commentators claim that this relationship is fraught with the risk of actual or perceived improper influence.

Calls for increased transparency in relationships with HCPs as well as consistency in how companies are regulated continue to grow, with the aim of ensuring integrity and increasing public confidence in the industry and the health care system. The pressure for change has been building for years both in Australia and overseas, especially in the United States.

So what has led to the recent explosion of interest?

The first point is that timing is everything. The MA Code is currently being reviewed by the ACCC and the Medical Technology Association of Australia's Code has been recently revised. The second point is that while those industry bodies are actively reviewing their Codes, other industry bodies have not acted. For example, the Generic Medicines Industry Association has not yet implemented a code of conduct even though a draft has been around for a number of years.

Amongst these developments, a recent event that has sparked debate is the concern about a Mediterranean cruise run by a generic pharmaceutical company, for which HCPs pay $8000-$10,000 each to attend. It includes some accredited educational events and approximately four company representatives are present. The cruise would breach the MA Code. However, the generic company declined to participate in MA's complaints resolution process, leading to the matter being referred by the Parliamentary Secretary for Health to the Therapeutic Goods Administration (TGA). The TGA ruled that the cruise did not breach the law, essentially because of a gap in the legislation, which regulates the promotion of particular products rather than the company's behaviour generally.

Immediately, calls for reform to hold generic and originator companies to the same standard were made.

Close on the heels of this issue, articles have recently been published in the general press which raise concerns about the relationship between medical device companies and HCPs. Well-known commentators of industry-HCP relationships also seized upon the opportunity to raise other concerns such as the ineffectiveness of complementary medicine regulation and the limited effectiveness, lack of enforceability and lack of transparency surrounding other complaints processes, especially that of the Complaints Resolution Panel.

At around the same time, the US regulators fined a leading pharmaceutical company US$2.3 billion for inappropriate promotion of its now withdrawn prescription medicine.

These events have led some to consider the need for reform across the industry.

A unified approach?

At the instigation of the Parliamentary Secretary for Health, the first stakeholder consultation meeting to consider possible reforms was held on 17 September 2009. No doubt, the coming months will see further activity.

The two broad themes that are being championed in the context of the reform proposals are increased consistency and transparency.

Currently, the regulation of promotional practices varies between product types and depends on the medium in which a claim is made or the context in which conduct occurs. The complaints processes and sanctions for inappropriate conduct are also different.

The drive to hold companies to the same high ethical standards may help to set a more level playing field. However, achieving this requires a sophisticated approach and further consultation and consideration is clearly needed. For example:

  • Any convergence in approach needs to still reflect the different legal restrictions on advertising for prescription medicines, medical devices, OTC products and complementary medicines. The most obvious difference is whether or not those products can be advertised to consumers.
  • Is it practical for a single code to cover different industry groups and products? Only some standards are of general application. A balance needs to be struck between consistency and retaining the scope to introduce tailored measures that enable industry members to collaborate and set best practice. Effective complaints procedures and sanctions are at the core of any industry code.
  • Should the existing hybrid model of legal regulation and industry codes be retained? What is the balance to be struck between legal requirements and voluntary codes of conduct?

What can companies do?

Many companies, via the relevant industry association, will be aware of the proposed reforms and have at least an indirect opportunity to participate in the consultation process. We will have to wait and see what the ultimate responses and outcomes will be.

At the individual company level, the current focus on the appropriateness of relationships between industry and HCPs is an incentive to ensure companies are implementing best practice compliance and risk management policies and procedures.

Pharmaceutical companies should also use the coming months to prepare for the expected changes to the MA Code. Clayton Utz can advise you on all aspects of compliance including preparation and implementation of new training modules, contract review, compliance program updates and managing risks arising under the Trade Practices Act 1974 (Cth).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Mondaq Advice Centre (MACs)
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.